Fig. 2: Waterfall, swimmer, and spider plots by dose level in the 4.8 and 6.0 mg/kg cohorts of HER2-positive breast cancer patients (n = 58). | npj Breast Cancer

Fig. 2: Waterfall, swimmer, and spider plots by dose level in the 4.8 and 6.0 mg/kg cohorts of HER2-positive breast cancer patients (n = 58).

From: Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours

Fig. 2

a Waterfall plot: maximal change in tumour target lesion size from baseline using RECIST v1.1 for patients with at least one posttreatment radiographic evaluation. The length of the bar represents the maximal decrease or minimal increase in the target lesion(s). b The swimmer plot shows the response and durations of response in the evaluated patients. c Change in individual tumour burden over time from baseline assessed using RECIST v1.1. Tumour response was assessed before treatment and once every 9 weeks until progressive disease, initiation of a new antitumour therapy, or withdrawal of consent.

Back to article page